JP MORGAN/CALL/BOSTON SCIENTIFIC/76/0.1/16.08.24 | Market Closed - Börse Stuttgart 11:28:15 2024-05-31 EDT | ||
| 0.43 EUR | -10.42% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.43 | -10.42% |
| 24-05-30 | 0.48 | +4.35% |
| 24-05-29 | 0.46 | -6.12% |
| 24-05-28 | 0.49 | -5.77% |
| 24-05-27 | 0.52 | +15.56% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:28 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK4KTD |
| ISIN | DE000JK4KTD1 |
| Date issued | 2024-03-06 |
| Strike | 76 $ |
| Maturity | 2024-08-16 (75 Days) |
| Parity | 10 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.52 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.03 € |
| Spread % | 6.00% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
75.57
USD
Average target price
82.06
USD
Spread / Average Target
+8.59%
- Stock Market
- Warrants
- Warrant
